GlassScriptPhysician profile
Kieron Dunleavy
NPI 1154610467
$139,172.22
in general payments reported to CMS, 2019-2025
34 companies · $14K in 2025
The $14K reported for 2025 was more than what 84% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,785 · 2020: $18K · 2021: $13K · 2022: $32K · 2023: $33K · 2024: $24K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $53K · Travel and Lodging: $16K · Food and Beverage: $2,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $52,749.00 |
| Travel and Lodging | $16,147.47 |
| Food and Beverage | $2,538.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $22,349.15 | 2022-2024 | |
| Chugai Pharmaceutical Co., LTD. | $19,857.17 | 2023 | |
| Beigene USA, INC. | $13,872.37 | 2022-2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $13,110.96 | 2019-2025 | Calquence |
| Janssen Research & Development, LLC | $11,605.53 | 2025 | Darzalex |
| Abbvie INC. | $8,591.07 | 2020-2025 | Venclexta, Epkinly |
| Amgen INC. | $8,512.35 | 2019-2023 | Blincyto |
| Kite Pharma, INC. | $6,770.06 | 2019-2024 | Yescarta |
| Janssen Scientific Affairs, LLC | $6,462.50 | 2020-2023 | Imbruvica |
| Incyte Corporation | $6,119.16 | 2020-2025 | Monjuvi |
| Daiichi Sankyo INC. | $4,488.50 | 2021 | |
| Acrotech Biopharma INC. | $4,477.27 | 2024 | Beleodaq |
| Genentech USA, INC. | $2,809.31 | 2019-2025 | Venclexta, Polivy |
| Genentech, INC. | $2,310.00 | 2020 | |
| Karyopharm Therapeutics INC. | $2,295.00 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,076.00 | 2023 | |
| Morphosys, US INC. | $1,150.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $900.00 | 2019 | |
| National Marrow Donor Program | $345.40 | 2022-2023 | |
| Seagen INC. | $342.89 | 2019-2023 | Adcetris |
| Pfizer INC. | $248.27 | 2024-2025 | |
| Verastem, INC. | $94.42 | 2019 | |
| Beone Medicines USA, INC. | $77.74 | 2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $64.99 | 2021 | |
| Janssen Biotech, INC. | $50.81 | 2025 | Carvykti, Erleada |
| Stemline Therapeutics INC. | $44.96 | 2025 | Orserdu |
| Tersera Therapeutics LLC | $35.26 | 2025 | Xermelo |
| Syndax Pharmaceuticals, INC. | $31.56 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.08 | 2024 | Ninlaro |
| Celgene Corporation | $28.36 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $22.08 | 2025 | Lynozyfic |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kieron Dunleavy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.